ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ArTara Therapeutics (TARA) announced the grant of inducement stock options totaling 4,100 shares to two new employees at an exercise price of $24.02 per share, equivalent to the May 1, 2020 closing price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ArTara Therapeutics (TARA) announced the grant of inducement stock options totaling 4,100 shares to two new employees at an exercise price of $24.02 per share, equivalent to the May 1, 2020 closing price. These options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter. The Compensation Committee approved these awards in line with NASDAQ Listing Rule 5635(c)(4). ArTara focuses on developing treatments for rare diseases, including TARA-002 for lymphatic malformations and IV choline chloride for intestinal failure-associated liver disease.
Positive
- Grant of stock options may enhance employee retention and incentivize new talent.
- Focus on rare diseases addresses significant unmet needs, potentially expanding market opportunity.
Negative
- None.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was -2.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 4,100 shares of common stock to two new employees.
Each stock option has an exercise price per share equal to
The Compensation Committee of ArTara’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).
About ArTara Therapeutics
ArTara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. ArTara’s current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company’s lead program, TARA-002, is being developed for the treatment of lymphatic malformations. ArTara’s second program, IV choline chloride, is a phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease.
Company Contact:
Blaine Davis
ArTara Therapeutics
Blaine.Davis@artaratx.com
646-844-0337
Media Contact:
Karen O’Shea, Ph.D.
LifeSci Communications
koshea@lifescicomms.com
929-469-3860
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.